France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment

According to the ministry’s press release, the price decrease for the drugs Harvoni and Sovaldi are described as “very substantial”. New prices are expected to come into effect in April. For Sovaldi, it will drop from €41,000 euros to less than €28,700 euros for the treatment of hepatitis C, it said.

As Intellectual Property Watch says, the new prices will allow continued universal access to hepatitis C for patients in France, the release said. Hepatitis C treatments are integrally supported by the French social security system, which will benefit from those new prices, it added.